The story appears on

Page A12

December 12, 2011

GET this page in PDF

Free for subscribers

View shopping cart

Related News

Home » Feature

New hope for women with breast cancer

BREAST cancer experts are cheering what could be some of the biggest advances in more than a decade: two new medicines that significantly delay the time until women with very advanced cases get worse.

In a large international study, an experimental drug from Genentech called pertuzumab held cancer at bay for a median of 18 months when given with standard treatment, versus 12 months for others given only the usual treatment. It also strongly appears to be improving survival, and follow-up is continuing to see if it does.

"You don't see that very often. ... It's a spectacular result," said one study leader, Dr Sandra Swain, medical director of Washington Hospital Center's cancer institute in the United States.

In a second study, another drug long used in organ transplants but not tried against breast cancer - everolimus, sold as Afinitor by Novartis AG - kept cancer in check for a median of 7 months in women whose disease was worsening despite treatment with hormone-blocking drugs. A comparison group that received only hormonal medicine had just a 3-month delay in disease progression.

Afinitor works in a novel way, seems "unusually effective" and sets a new standard of care, said Dr Peter Ravdin, breast cancer chief at the UT Health Science Center in San Antonio. He has no role in the work or ties to drugmakers.

Results were released last Wednesday at the San Antonio Breast Cancer Symposium and some were published online by the New England Journal of Medicine. They come a few weeks after federal approval was revoked for another Genentech drug, Avastin, that did not meaningfully help breast cancer patients. It still is sold for other tumor types.

The new drugs are some of the first major developments since Herceptin came out in 1998. It has become standard treatment for a certain type of breast cancer.

"These are powerful advances ... an important step forward," said Dr Harold Burstein, a breast expert at Dana-Farber Cancer Institute in Boston who had no role in the studies.

A reality check: The new drugs are likely to be very expensive - up to US$10,000 a month - and so far have not proved to be cures. Doctors hope they might be when given to women with early-stage cancers when cure is possible, rather than the very advanced cases treated in these studies.

Even short of a cure, about 40,000 American women each year have cancer that spreads beyond the breast, and treatment can make a big difference in their lives.

Rachel Midgett is an example. The 39-year-old Houston woman has breast cancer that spread to parts of her liver, yet she recently ran a half-marathon in Las Vegas. She has had three scans since starting on Afinitor nine months ago, and "every time, my liver lesions keep shrinking," she said.

"My quality of life has been wonderful. It's amazing. I have my hair. ... If you saw me you wouldn't even know I have cancer."

Genentech, part of the Switzerland-based Roche Group, applied last Tuesday to the US Food and Drug Administration for permission to sell pertuzumab as initial treatment for women like those in the study.

The drug targets cells that make too much of a protein called HER2 - about one of every four or five breast cancer cases. Herceptin attacks the same target but in a different way, and the two medicines complement each other.

The study tested the combination in 808 women from Europe, North and South America and Asia and found a 6-month advantage in how long the cancer stayed stable. All women also received a chemotherapy drug, docetaxel.

So far, 165 deaths have occurred - 96 among the 406 women given Herceptin and chemo alone, and only 69 among the 402 women also given pertuzumab. Doctors won't know whether the drug affects survival until there are more deaths.




 

Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.

沪公网安备 31010602000204号

Email this to your friend